Author/Authors :
Besnard، Jean-Claude نويسنده , , Guilloteau، Denis نويسنده , , Baulieu، Jean-Louis نويسنده , , Resche، Isabelle نويسنده , , Bardies، Manuel نويسنده , , Chauvet، Alain Faivre نويسنده , , Lecloirec، Joseph نويسنده , , Malhaire، Jean-Pierre نويسنده , , Thomas، Eric نويسنده , , Faurous، Patrick نويسنده , , Sassolas، Geneviève نويسنده , , Pourcelot، Léandre نويسنده , , Chatal، Jean-François نويسنده ,
Abstract :
Dosimetry and therapeutic application of [131I]-Tyr3-octreotide were evaluated in three patients with metastatic paraganglioma and carcinoid tumor. The in vitro stability of [131I]Tyr3-octreotide was verified. Tumor uptake and residence time were between 0.02 and 0.1% and 0.5 to 9.8 h, respectively. The calculated tumor radiation doses were between 0.105 and 0.696 mGy·MBq-1. No intolerance or adverse effects were observed after the therapeutic doses (3.3¯6.6 GBq). A partial tumor response was obtained in one patient and no response occurred in two patients.
Keywords :
Technetium-99m , Streptavidin/biotin , Receptor binding , Specific activity
